Stockholm-based multinational pharma company, Medivir AB, has announced a partnership with Hyderabad-based GVK Biosciences Pvt Ltd.
Medivir has conducted a review of its discovery research operations and had identified the opportunity to improve quality and efficiency through a partnership with GVK BIO.
The partnership will consolidate and strengthen all current outsourced synthetic chemistry in a single facility at GVK BIO’s Integrated Discovery Research Campus, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds, according to a release issued here on Tuesday.
The company has also reorganised some of its global operations. “This reorganisation and resource optimisation will improve efficiency and enhance our ability to deliver well-differentiated candidate drugs into our development pipeline, while over time reducing overall research costs and improving cost flexibility, and we look forward to a productive partnership with our colleagues at GVK BIO,’’ Niklas Prager, Medivir CEO, said.
"Medivir chose GVK BIO over several other CROs on the basis of its scientific strength and its ability to perform integrated research with Chemistry and Biology. We look forward to delivering significant value to Medivir shareholders and to a productive partnership,” said Manni Kantipudi, CEO, GVK BIO.